Medistem Laboratories, Inc. (MDSM.OB) is moving forward with its second pipeline candidate known as, Tolerostem(TM).
This procedure is a cellular therapy platform aimed at controlling harmful immunological responses through the use of adult stem cells undergoing a proprietary modification.
If approved for human use, the Tolerostem(TM) platform could make a significant contribution in the treatment of multiple autoimmune diseases ranging from rheumatoid arthritis, to multiple sclerosis, to Type I diabetes.
Currently Medistem is in discussions with immunology laboratories for performing preclinical safety and efficacy experiments to hopefully enable Investigational New Drug (IND) filing with the FDA in the last quarter of 2007. If accepted by the FDA, the company will then work towards initiating U.S. clinical trials.
Let us hear your thoughts below: